Chemotherapy-Induced Myelosuppression in SCLC

ASCO 2022 Conference Coverage
A

ASCO 2022 on Phase 3 ATLANTIS Trial: Analysis of Patients With Relapsed SCLC Receiving Single-Agent Lurbinectedin

By ASCO 2022 Conference Coverage FEATURING Alejandro Navarro
By ASCO 2022 Conference Coverage FEATURING Alejandro Navarro
253 views
June 15, 2022
Comments 0
Login to view comments. Click here to Login
11:05

Myelopreservation With the CDK4/6i Trilaciclib in Patients With SCLC…

UNC Lineberger Comprehensive Cancer Center

J. Weiss

497 views
22:07

Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression in E…

Jerome Goldschmidt

513 views
15:31

Importance of Addressing Myelosuppression in Chemotherapy Patients

Edgardo Santos​

184 views
15:30

Small Cell Lung Cancer: A Brief Review of the Treatment Landscape

Dana-Farber Cancer Institute

J. Sands

611 views
20:11

Myelosuppression in ES-SCLC Therapy

Maen Hussein

242 views
28:56

Nebraska Oncology Society 2022 SCLC Management Updates

Nebraska Oncology Society

T. Leal

179 views
27:09

Treatment Landscape of SCLC

Edgardo Santos​

189 views
22:38

Trilaciclib and the Economic Value of Multilineage Myeloprotection F…

Ivo Abraham

640 views
04:05

ASCO 2022 on KEYVIBE-008: Randomized, Phase 3 Study of 1L Vibostolim…

ASCO 2022 Conference Coverage

J. Sands

510 views
15:49

ASCO 2022 on Stereotactic Radiosurgery vs. WBRT in SCLC and Intracra…

ASCO 2022 Conference Coverage

K. Gaebe

431 views
14:23

ASCO 2022 Impact of Trilaciclib on Multilineage Chemo-Induced Myelos…

ASCO 2022 Conference Coverage

J. Goldschmidt

93 views
25

Lecture Summary - ASCO 2022 on KEYVIBE-008: Randomized, Phase 3 Stud…

ASCO 2022 Conference Coverage

J. Sands

43 views
01:01

Lecture Summary - ASCO 2022 on Stereotactic Radiosurgery vs. WBRT in…

ASCO 2022 Conference Coverage

K. Gaebe

47 views
52

Lecture Summary - ASCO 2022 Analysis of Patients With Relapsed SCLC …

ASCO 2022 Conference Coverage

A. Navarro

23 views